Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Kroger, Linda A ^a   DeNardo, Sally J ^a   DeNardo, Gerald L ^a   Xiong, Cheng Yi ^a   Winthrop, Michelle D ^a   Gumerlock, Paul H ^a  

^a Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CHELATING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1 CU 67; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; COPPER; HLA DR ANTIGEN; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; RADIOIMMUNOTHERAPY; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; IMMUNOLOGY; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; COPPER RADIOISOTOPES; GENES, BCL-2; HLA-DR ANTIGENS; HUMANS; LYMPHOMA; MICE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOIMMUNOTHERAPY; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032589758     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Armitage, J. O. Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med., 328: 1023-1030, 1993.
2. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.
3. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W., Milik, A. W., Estes, J., Tuck, M., Regan, D., Fisher, S., Glenn, S. D., and Wahl, R. L. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol., 14: 1974-1981, 1996.
4. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
5. Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., Izon, D. O., Burger, K., Swayne, L. C., Belisle, E., Hansen, H. J., and Pinsky, C. M. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J. Clin. Oncol., 9: 548-564, 1991.
6. 131I-Lym-1 antibody. Cancer Biother. Radiopharm., 13: 239-254, 1998.
7. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J. Clin. Oncol., 16: 3246-3256, 1998.
8. DeNardo, G. L., O'Donnell, R. T., and DeNardo, S. J. A revolution in the treatment of non-Hodgkin's lymphoma. Cancer Biother Radiopharm, 13: 213-223, 1998.
9. Jungerman, J. A., Yu, K. H., and Zanelli, C. I. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy. Int. J. Appl. Radiat. Isot., 35: 883-888, 1984.
10. 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with Burkitt's lymphoma (Raji). Clin. Cancer Res., 3: 71-79, 1997.
11. 67Cu-labelled anticolon carcinoma monoclonal antibody MAB35. Q. J. Nucl. Med., 39: 80, 1998.
12. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma J. Nucl. Med., in press, 1999.
13. 67Cu-2IT-BAT-Lym-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. Anticancer Res., 18: 2779-2788, 1998.
14. Moi, M. K., Meares, C. F., McCall, M. J., Cole, W. C., and DeNardo, S. J. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem., 148: 249-253, 1985.
15. Kukis, D. L., Li, M., and Meares, C. F. The selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorg. Chem., 32: 3981-3982, 1993.
16. Tsujimoto, Y., Cossman, J., Jaffe, E., and Croce, C. Involvement of the bcl-2 gene in human follicular lymphoma. Science (Washington DC), 228: 1440-1443, 1985.
17. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
18. Williams, G. T. Programmed cell death: apoptosis and oncogenesis. Cell, 65: 1097-1098, 1991.
19. 2/M-phase block and other radiobiological parameters. Radiat. Res., 135: 24-31, 1993.
20. Fowler, J. F. Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys., 18: 1261-1269, 1990.
21. Dillehay, L. E., and Williams, J. R. Radiobiology of dose-rate patterns achievable in radioimmunoglobulin therapy. Front. Rad. Ther. Oncol., 24: 96-103, 1990.
22. Hall, E. J., and Marchese, I. Dose-rate effects in normal and malignant cells of human origin. Br. J. Radiol., 60: 573-576, 1987.
23. Macklis, R. M., Beresford, B. A., Palayoor, S., Sweeney, S., and Humm, J. L. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int. J. Radiat. Oncol. Biol. Phys., 27: 643-650, 1993.
24. Gumerlock, P. H., Edwards, B. F., Deitch, A. D., and Meyers, F. J. Human renal clear cell carcinoma: establishment and characterization of a new cell line (G-2101). In Vitro Cell Dev. Biol., 24:429-434, 1988.
25. Rose, L. M., Gunasekera, A. H., DeNardo, S. J., DeNardo, G. L., and Meares, C. F. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol. Immunother., 43: 26-30, 1996.
26. Epstein, A. L., Marder, R. J., Winter, J. N., Stathopoulos, E., Chen, F. M., Parker, J. W., and Taylor, C. R. Two new monoclonal antibodies, Lym-1 and Lym-2. reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res., 47: 830-840, 1987.
27. Hu, E., Epstein, A. L., Naeve, G. S., Gill, I., Martin, S., Sherrod, A., Nichols, P., Chen. D., Mazumder, A., and Levine, A. M. A phase Ia clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hematol. Oncol., 7: 155-166, 1989.
28. DeNardo, S. J., Gumerlock, P. H., Winthrop, M. D., Mack, P. C., Chi, S. G., Lamborn, K. R., Shen, S., Miers, L. A., deVere White, R. W., and DeNardo, G. L. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. Cancer Res., 55: 5837-5841, 1995.
29. Madewell, B. R., Gumerlock, P. H., Saunders, K. A., Meyers, F. J., Kraegel, S. A., and Kawasaki, E. S. Canine and bovine ras family expression detected and discriminated by use of polymerase chain reaction. Anticancer Res., 9: 1743-1749, 1989.
30. Winthrop, M. D., DeNardo, S. J., Muenzer, J. T., Chi, S. G., and Gumerlock, P. H. p53-independent response of a human breast cancer xenograft to radioimmunotherapy. Cancer (Phila.), 80: 2706-2712, 1997.
31. Gumerlock, P. H., Meyer, F. J., Kokoris, S. P., Wong, G., McCormick, F. P., and deVere White, R. W. RAS enzyme-linked immunoblot assay discriminates p21 species: a technique to dissect gene family expression. Anal. Biochem., 180: 158-168, 1989.
32. Duthu, A., Debuire, B., Romano, J., Ehrhart, J. C., Fiscella, M., May, E., Appella, E., and May, P. p53 mutations in Raji cells: characterization and localization relative to other Burkitt's lymphomas. Oncogene, 7: 2161-2167, 1992.
33. Wyllie, A. H. Glucocorticoid induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (Lond.), 284: 555-556, 1980.
34. Igarishi, T., Yoshida, S., and Miyamoto, T. Radiation-induced interphase death observed in human T cell lymphoma cells established as a nude mouse line. Exp. Hematol., 18: 824-831, 1990.
35. Kerr, J. F., and Searle, J. Apoptosis. Its nature and kinetic role. In: R. E. Meyn and H. R. Withers (eds.), Radiation Biology in Cancer Research, pp. 367-384. New York: Raven Press, 1980.
36. Trauth, B. C., Klas, C., Peters, A. M., Matzku, S., Moller, P., Falk, W., Debatin, K., and Kramer, P. Monoclonal antibody mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301-304, 1989.
37. Vriesendorp, H. M., Herpst, J. M., Germack, M. A., Klein, J. L., Leichner, P. K., Loudenslager, D. M., and Order, S. E. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87-01. J. Clin. Oncol., 9: 918-928, 1991.
38. 90Y lymphoma therapy. Cancer (Phila.), 73: 966-973, 1994.